Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
Today Merck & Co. (NYSE: MRK) announced that Keytruda has failed the Phase 3 clinical trial KEYNOTE-412 evaluating…
Recent Report Highlights Success in FDA Subgroup Approval & Treatment Arm Data
A recent report published by the American Association for Cancer Research titled Subgroup Analyses in Oncology Trials: Regulatory…